Dihydralazine

證據等級: L5

預測適應症: 10 個

Dihydralazine: From Hypertensive Crisis to Heart Disease

One-Sentence Summary

Dihydralazine is a direct-acting arteriolar vasodilator historically used for hypertensive crises and as an adjunct in congestive heart failure, though it holds no current drug registration in India. The TxGNN model predicts it may be effective for Heart Disease, with 1 clinical trial and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Hypertensive crisis; adjunct in congestive heart failure (historical use; no India registration)
Predicted New Indication	Heart Disease
TxGNN Prediction Score	99.97%
Evidence Level	L3
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is currently unavailable from DrugBank. Based on available literature, Dihydralazine belongs to the hydrazinophthalazine class and functions as a direct arteriolar vasodilator. It reduces systemic vascular resistance (afterload) without directly increasing myocardial contractility. Several French and European clinical studies from the 1980s (marketed as Nepressol) documented its use in NYHA class III–IV congestive heart failure as an adjunct to digitalis and diuretics, based on this afterload-reduction rationale.

The mechanistic link to heart disease is biologically plausible in the short term: reducing afterload allows a failing heart to increase cardiac output. However, this benefit is self-limiting. Pure arteriolar vasodilation reflexively activates the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, leading to compensatory sodium retention, tachycardia, and ultimately tachyphylaxis — exactly the pattern documented in the landmark 1984 European Heart Journal study (PMID 6479183), where long-term benefit was lost compared to placebo.

The TxGNN prediction therefore reflects an established but historically superseded pharmacological association. Dihydralazine was an early vasodilator used before ACE inhibitors demonstrated superior neurohormonal blockade and survival benefit. One active Phase 3 trial (NCT05230901) is re-exploring dihydralazine specifically in the context of post-TAVI myocardial fibrosis alongside spironolactone — a more targeted hypothesis that may offer a rationale for narrow re-evaluation, but cannot yet be attributed to dihydralazine’s individual contribution.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05230901	Phase 3	Recruiting	300	Evaluates antifibrotic therapy for regression of myocardial fibrosis post-TAVI in aortic stenosis patients with high fibrotic burden. Three arms: standard of care alone, Spironolactone + standard of care, or Spironolactone + Dihydralazine + standard of care. Dihydralazine is a combination partner, not the primary study drug; efficacy attributable to it specifically cannot be determined from this design.

⚠️ The sole identified trial has low direct relevance to Dihydralazine as a therapy for heart disease (Relevance Grade C). No trials testing Dihydralazine as the primary intervention for heart disease were identified.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1420010	1992	RCT	Br J Obstet Gynaecol	Compared epoprostenol vs dihydralazine in acute hypertensive crisis of pregnancy; dihydralazine served as the active comparator, supporting its established role in acute BP reduction
29974489	2018	Network Meta-Analysis	Br J Clin Pharmacol	Network meta-analysis of antihypertensives for severe hypertension in pregnancy; includes comparative efficacy and safety data for dihydralazine vs labetalol, nifedipine and others
3075406	1988	Comparative Clinical Study	Acta Physiol Hung	Short-term comparison of captopril (Lopirin, Tensiomin) vs dihydralazine in 15 patients with severe heart failure (NYHA III–IV); ACE inhibitors and dihydralazine both showed hemodynamic benefit acutely
6479183	1984	Clinical Study	Eur Heart J	Long-term dihydralazine vs placebo in 14 severe CHF patients refractory to digitalis/diuretics; acute hemodynamic benefits confirmed but long-term efficacy lost — key tachyphylaxis evidence
6803467	1982	Clinical Study	Z Kardiol	Acute and chronic hemodynamic effects of dihydralazine in severe congestive heart failure both at rest and during exercise
7209863	1980	Clinical Study	Therapie	Tolerance and complications of dihydralazine treatment in severe heart failure; early clinical safety characterization
22534703	2012	Case Report	Med Sci Monit	Management of NYHA class III/IV heart failure (LVEF 13%) during pregnancy; dihydralazine considered as part of multi-drug regimen in a life-threatening cardiac situation
8497771	1993	Review	Schweiz Med Wochenschr	Review of hypertensive crisis management; discusses hemodynamic mechanisms and lists dihydralazine among available agents with notes on endothelial damage pathophysiology
1695297	1990	Animal Study	J Cardiovasc Pharmacol	Hemodynamic comparison of isradipine vs dihydralazine in atherosclerotic and normal rabbits; dihydralazine produced arteriolar vasodilation but with less favorable organ perfusion profile than calcium antagonist
15201535	2004	Cohort	J Hypertension	Plasma volume and hemodynamic disturbances in hypertensive pregnancy; provides physiological context for dihydralazine’s afterload-targeting mechanism in cardiovascular disease states

Safety Considerations

No structured safety data (key warnings, contraindications, or drug interactions) was returned from the standard sources. Please refer to the package insert for safety information.

Literature-derived safety signals worth flagging before any further use:

Drug-induced autoimmune hepatitis: Dihydralazine is metabolized by CYP1A2, and multiple case series and mechanistic studies (PMID 2347920, PMID 1513326, PMID 9241657) have documented dihydralazine-induced hepatitis characterized by anti-CYP1A2 (anti-liver microsomal) autoantibodies. This is a rare but potentially serious idiosyncratic reaction requiring hepatic monitoring.

Acetylator phenotype dependency: Dihydralazine is acetylated by hepatic N-acetyltransferase (NAT2); slow acetylators may have higher plasma levels and elevated risk of drug-induced lupus-like syndrome — a known class effect of hydrazinophthalazines.

Pregnancy context: Multiple studies used dihydralazine in hypertensive emergencies of pregnancy, but a 2018 network meta-analysis (PMID 29974489) suggests newer agents (labetalol, nifedipine) may have more favorable profiles.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction for heart disease reflects a known pharmacological history, not a new repurposing opportunity. Dihydralazine was clinically evaluated for heart failure in the 1980s and was superseded by ACE inhibitors and beta-blockers due to tachyphylaxis and the lack of neurohormonal benefits. The only active clinical trial uses dihydralazine as a combination partner in a highly specific post-TAVI fibrosis setting, making it impossible to derive independent efficacy conclusions. With zero India market registrations and no complete safety data on file, the current evidence base does not support advancing this candidate.

To proceed, the following is needed:

Obtain complete MOA and safety data from DrugBank API and the EMA/ANSM (French) package insert for Nepressol
Clarify whether the NCT05230901 trial can generate dihydralazine-specific efficacy and safety data via subgroup or secondary analysis
Define a precise sub-indication (e.g., post-TAVI myocardial fibrosis, hypertensive heart disease with fibrotic remodeling) where dihydralazine’s mechanism may offer benefit beyond current standard of care
Assess NAT2 acetylator phenotype implications for patient stratification and safety risk management
Review the full TFDA/India CDSCO database to confirm absence of any historical registration and evaluate regulatory pathway feasibility
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.